An announcement from Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) is now available.
Shandong Xinhua Pharmaceutical Company Limited has received approval for the change of marketing license holder for its Rosuvastatin calcium tablets from the National Medical Products Administration. This approval follows a technology transfer contract with Suzhou Dongrui Pharmaceutical Company, allowing Xinhua Pharmaceutical to acquire the marketing and sales rights for the drug, which could enhance its market position and operational capabilities in the pharmaceutical industry.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited is a pharmaceutical company based in China, focusing on the development and production of prescription drugs, including Rosuvastatin calcium tablets.
YTD Price Performance: -3.27%
Average Trading Volume: 3,104,833
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$9.12B
See more data about 0719 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com